Previous Article | Next Article 
Infection and Immunity, November 2000, p. 6196-6201, Vol. 68, No. 11
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Cryptococcus neoformans Gene
DHA1 Encodes an Antigen That Elicits a Delayed-Type
Hypersensitivity Reaction in Immune Mice
M. Alejandra
Mandel,1
Greg G.
Grace,2,3
Kris I.
Orsborn,2,3
Fredda
Schafer,4
Juneann W.
Murphy,4
Marc J.
Orbach,1 and
John N.
Galgiani2,3,*
Medical and Research Services, Veterans
Affairs Medical Center,2 and Department
of Medicine, College of Medicine,3 and
Department of Plant Pathology, College of
Agriculture,1 University of Arizona, Tucson
Arizona, and Department of Microbiology, University of
Oklahoma, Oklahoma City, Oklahoma4
Received 28 June 2000/Accepted 25 July 2000
 |
ABSTRACT |
When mice are vaccinated with a culture filtrate from
Cryptococcus neoformans (CneF), they mount a protective
cell-mediated immune response as detected by dermal delayed-type
hypersensitivity (DTH) to CneF. We have identified a gene
(DHA1) whose product accounts at least in part for the DTH
reactivity. Using an acapsular mutant (Cap-67) of C. neoformans strain B3501, we prepared a culture filtrate
(CneF-Cap67) similar to that used for preparing the commonly used skin
test antigen made with C. neoformans 184A (CneF-184A). CneF-Cap67 elicited DTH in mice immunized with CneF-184A.
Deglycosylation of CneF-Cap67 did not diminish its DTH activity.
Furthermore, size separation by either chromatography or differential
centrifugation identified the major DTH activity of CneF-Cap67 to be
present in fractions that contained proteins of approximately 19 to 20 kDa. Using N-terminal and internal amino acid sequences derived from
the 20-kDa band, oligonucleotide primers were designed, two of which
produced a 776-bp amplimer by reverse transcription-PCR (RT-PCR) using
RNA from Cap-67 to prepare cDNA for the template. The amplimer was used
as a probe to isolate clones containing the full-length
DHA1 gene from a phage genomic library prepared from strain
B3501. The full-length cDNA was obtained by 5' rapid amplification of
cDNA ends and RT-PCR. Analysis of DHA1 revealed a
similarity between the deduced open reading frame and that of a
developmentally regulated gene from Lentinus edodes
(shiitake mushroom) associated with fruiting-body formation. Also, the
gene product contained several amino acid sequences identical to those determined biochemically from the purified 20-kDa peptide encoded by
DHA1. Recombinant DHA1 protein expressed in
Escherichia coli was shown to elicit DTH reactions similar
to those elicited by CneF-Cap67 in mice immunized against C. neoformans. Thus, DHA1 is the first gene to be cloned
from C. neoformans whose product has been shown to possess
immunologic activity.
 |
INTRODUCTION |
Cryptococcus neoformans
is a human fungal pathogen that typically affects patients with
underlying T-cell deficiencies such as occur with AIDS or during
immunosuppressing therapy (2, 10, 11). This predilection for
immunosuppressed patients suggests that normal people may resist
infection with C. neoformans by competent immune responses
to antigenic stimulation. There is considerable experimental support
for this concept from the murine model of cryptococcosis (3,
6). For example, vaccination with a C. neoformans
culture filtrate antigen (CneF) in complete Freund's adjuvant (CFA)
induces protection against a subsequent cryptococcal infection as well
as dermal delayed-type hypersensitivity (DTH) response(s) to
cryptococcal antigen (17). CneF can be used in vitro to
detect anticryptococcal cell-mediated immune (CMI) responses of
lymphocytes from Cryptococcus-infected patients (7).
CneF has been separated into three main components:
glucuronoxylomannan, galactoxylomannan, and mannoprotein
(15). The MP fraction is the primary component recognized by
the anticryptococcal CMI response in mice (15). It is
presumed that the MP fraction also induces the specific CMI response
detected by CneF and that other components in CneF may play a
modulatory role. However, little is known about the exact antigen or
antigens which elicit the anticryptococcal CMI response.
Here we report that CneF prepared from an acapsular mutant of C. neoformans stimulates a DTH response in mice immunized with antigen prepared from a weakly virulent encapsulated strain of C. neoformans. Biochemical fractionation of CneF from the acapsular mutant further localized DTH reactivity to a specific fraction. Furthermore, we have cloned a gene encoding a putative protein from
this fraction, and its expression product has shown DTH reactivity in
mice analogous to the native antigen in CneF.
 |
MATERIALS AND METHODS |
Fungal strains.
C. neoformans strains 184A (serotype
A), described by Murphy and Cozad (12), and Cap-67, an
acapsular mutant derived from strain B-3501 (serotype D), described by
Jacobson et al. (8), were used in this work. Cap-67 was
selected for our studies because it does not produce the
high-molecular-weight polysaccharide glucuronoxylomannan, thus
simplifying protein purification.
Preparation of CneF from different strains.
A C. neoformans filtrate from the weakly virulent encapsulated strain
184A (CneF-184A) was prepared by growing the culture in a chemically
defined liquid medium for 5 days as described previously
(1). After the culture was treated with 2% formalin, the
C. neoformans cells were removed by filtration. The
supernatant was subjected to a tangential-flow system to exclude all
molecules smaller than 30 kDa (Pellicon OM-141; Millipore, Bedford,
Mass.). The retentate was washed with 10 volumes of physiological
saline solution, concentrated 10-fold, filter sterilized, and stored at
20°C. Each preparation of CneF-184A was standardized against the
previous lot of CneF-184A for DTH reactivity in mice immunized with the
previous lot. CneF-184A has been used as a standard skin test antigen
for C. neoformans for the past 20 years (7, 13, 15,
16). The lot of CneF-184A used in these studies had a protein
concentration of 0.171 mg/ml as determined by the bicinchoninic acid
procedure (Pierce Chemical Co., Rockford, Ill.) and a carbohydrate concentration of 6.9 mg/ml as determined by the phenol-sulfuric acid
procedure (4).
The CneF from Cap-67 (CneF-Cap67) was prepared in a manner similar to
that for CneF-184A, except that the culture was grown in a different
defined medium consisting of 7.6 mM asparagine, 2 mM
MgSO4 · 7H2O, 22 mM
KH2PO4, 150 mM glucose, 3 mM thiamine, 18 mM
CaCl2 · 2H2O, and 13 mM
ZnSO4 · 7H2O. The retentate was collected and concentrated using a Minitan apparatus (Amicon, Beverly,
Mass.) with a molecular mass exclusion of 10 kDa.
Antigen fractionation.
CneF-Cap67 was lyophilized and
chemically deglycosylated with anhydrous hydrogen fluoride as described
by Shively (19). The resulting material was dialyzed
sequentially against 100% pyridine, 10% pyridine, and finally 10%
acetic acid. The retentate was then lyophilized and resuspended in
water. Insoluble material was removed by centrifugation at
10,000 × g for 5 min. The supernatant from this step,
referred to as HF-CneF-Cap67, was tested directly for its ability to
elicit a DTH reaction in immunized mice or was purified further as
indicated below. In comparison to CneF-Cap67, the carbohydrate content
of HF-CneF-Cap67 was reduced by more than 95% as shown by the
phenol-sulfuric assay for carbohydrates, staining of native
polyacrylamide gels with periodic acid-Schiff reagent, and development
of a lectin blot with concanavalin A (data not shown).
The HF-CneF-Cap67 was fractionated by chromatography on Sephadex G-75
Superfine (Pharmacia, Piscataway, N.J.). Based on analysis of these
fractions as detailed in Results, larger quantities of proteins with a
molecular mass range between 10 and 30 kDa were isolated by
differential centrifugal ultrafiltration (Centricon 30 and Centricon 10 [Amicon]) for amino acid sequencing.
Amino acid sequencing.
Protein preparations from
differential centrifugation were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted to
polyvinylidene difluoride, and individual bands were excised for amino
acid sequencing. N-terminal sequencing and total amino acid composition
measurement were performed at the University of Arizona Macromolecular
Structure Facility (Tucson, Az.). Digestion with trypsin or Lys-C and
internal sequencing of high-performance liquid chromotography (HPLC)
fractions were performed at the Harvard University Microchemistry
Facility (Cambridge, Mass.).
DNA isolation.
C. neoformans Cap-67 was grown for
48 h, and cells were recovered by centrifugation at
3,000 × g for 10 min and stored in 200-µl aliquots
in screw-cap 2.0-ml microcentrifuge vials at
80°C. Prior to use,
samples were thawed on ice, 1.2 ml of 0.5 mM glass beads was added, and
the tubes were completely filled with lysis buffer (100 mM Tris-HCl
[pH 7.5], 50 mM EDTA [pH 8.0], 1% SDS, 500 mM NaCl). The cells
were disrupted by shaking the vials in a minibead beater (Biospec
Products, Bartlesville, Okla.) at 4°C for three 20-s pulses at 80%
of maximum speed separated by 1-min pauses and then incubated for 20 min at 68°C. The homogenate was extracted with an equal volume of
phenol-chloroform-isoamyl alcohol (25:24:1). The aqueous supernatants
were extracted twice with 1 volume of chloroform-isoamyl alcohol
(24:1), and the DNA was precipitated with ethanol. The resulting DNA
was washed with 70% ethanol, dried at room temperature, and
resuspended in 100 µl of Tris-EDTA (TE) (pH 8.0).
RNA isolation.
Cultures of Cap-67 were grown under the same
conditions that were used to prepare CneF-Cap67 and were stored at
80°C in 2.0-ml microcentrifuge vials prior to extraction. Aliquots
were thawed on ice, and 840 µl of phenol-chloroform-isoamyl alcohol
(25:24:1) and 660 µl of extraction buffer (50 mM Tris-HCl [pH 7.5],
100 mM LiCl, 5 mM EDTA [pH 8.0], 1% [wt/vol] SDS, 1%
-mercaptoethanol) were added to each vial. The tubes were then
completely filled with 0.5-mm-diameter glass beads. The vials were
agitated in the minibead beater at 4°C five times for 20 s at
80% of maximum speed separated by 20-s rests. After this, the vials
were centrifuged for 5 min at full speed in a microcentrifuge. The
supernatant was extracted with 840 µl of phenol-chloroform-isoamyl
alcohol and subsequently with chloroform. The RNA was precipitated in 2 M (final concentration) LiCl, washed with 70% ethanol, air dried, and
resuspended in 25 µl of diethylpyrocarbonate-treated water.
cDNA synthesis.
First-strand cDNA was synthesized using 500 ng of Cap-67 RNA, 500 ng of oligo(dT)12-18, and the
SuperScript II RNase H
reverse transcriptase kit (Life
Technologies, Gaithersburg, Md.) as specified by the manufacturer.
After treatment with 2 U of RNase H (Life Technologies), 1 µl of
first-strand cDNA was used to synthesize the second strand with
Taq polymerase (Roche Molecular Biochemicals, Indianapolis,
Ind.) by standard procedures (18) in a GeneAmp PCR System
2400 (Perkin-Elmer, Foster City, Calif.). Based on N-terminal and
internal amino acid sequences, as described in Results, 14 degenerate
oligonucleotide primers were designed and synthesized. For experiments
with various combinations of these primers, 0.1 nmol of each degenerate
oligonucleotide was used under the following PCR conditions: one cycle
of 30 s at 94°C, 35 cycles of 20 s at 94°C, 30 s at
55°C, and 90 s at 72°C, followed by a final extension cycle of
5 min at 72°C. The PCR product from one pair (OAM51
[ACIACIGCIGCIAAYGGIGCIGC] and OAM46 [ACICCIGGIARIGCIGTRCARTCIAC]) was cloned using the TA cloning kit
(Invitrogen, Carlsbad, Calif.) as specified by the manufacturer and
transformed into Top10 cells (Invitrogen), generating clone pAM830.
The 5' rapid amplification of cDNA ends system (Life Technologies) was
performed as specified by the manufacturer, using 500 ng of Cap-67 RNA
to obtain the 5' end of the cDNA not present in pAM830. The
oligonucleotide primers used in this procedure were as follows: the
gene-specific primer 1 (GSP1) was OAM63 (ACCGGACACAAGACCAGA), GSP2 was OAM59 (AGTTGTTGCCGAGGACGATTG), and GSP3 was OAM51.
Cloning procedures and sequence analysis.
A
phage
genomic library created from C. neoformans strain B3501
(AIDS Research and Reference Reagent Program: Cryptococcus neoformans Genomic Library from Jeffrey Edman) was screened with the cDNA insert from pAM830 as a probe. DNAs from hybridizing clones
were excised from the
ZAP vector by the recommended procedure (Stratagene, La Jolla, Calif.).
Both strands of all clones were sequenced at the Laboratory of
Molecular Systematics and Evolution of the University of Arizona by
using the Applied Biosystems (ABI) PRISM dye terminator kit (Perkin-Elmer) and an ABI model 373 DNA sequencer. Sequence analyses were performed using the GCG sequence analysis software package (Genetics Computer Group Inc., Madison, Wis.), and protein comparisons were done through the National Center for Biotechnology Information (Bethesda, Md.) using the BLAST algorithm.
A C. neoformans strain B3501
phage cDNA library (AIDS
Research and Reference Reagent Program: Cryptococcus
neoformans cDNA Library) from Jeffrey Edman was used for some
experiments as indicated.
Protein expression.
cDNAs carrying the complete open reading
frame (ORF) were synthesized by reverse transcription-PCR (RT-PCR)
amplification as described above, using oligonucleotide primers OAM65
(GGGGAATTCGCCATGTTCTCGTCCACT) and OAM66
(GGGGAATTCATTTTACAGCTGGAGAGT). The following PCR conditions were used: one cycle of 30 s at 94°C, 35 cycles of 20 s at
94°C, 30 s at 60°C, and 90 s at 72°C, and a last cycle
of 10 min at 72°C. The amplified band was cloned and subsequently
subcloned into the EcoRI site of the expression vector
pET32a (Novagen, Madison, Wis.) to generate pAM888, which was used to
transform AD494 (DE3) pLysS bacterial cells.
Protein expression was performed by standard methods after induction
with 1 mM isopropyl-
-D-thiogalactopyranoside IPTG for 3 h. Protein samples were subjected to SDS-PAGE (8 and 10%
polyacrylamide gels) and stained with Coomassie blue or transferred to
nylon membranes (MSI, Westborough, Mass.) using a Trans-Blot SD semidry electrophoretic transfer cell (Bio-Rad, Hercules, Calif.). Fusion proteins were detected by Western blot hybridization using the S-Tag
Western blot kit (Novagen).
Protein purification was performed using the His-Bind resin and
purification kit (Novagen), as specified by the manufacturer, under
denaturing conditions (6 M guanidine-HCl). After elution with 300 mM
imidazole, proteins were concentrated using Centricon 30 and 10 concentrators (Amicon) for the fusion construct and control vector
alone, respectively. The fusion protein was partially renatured by
sequential washes of the protein concentrate in the Centricon column
with 4, 2, 1, and 0.5 M guanidine-HCl.
Induction and elicitation of an anticryptococcal DTH
response.
CBA/J mice were immunized subcutaneously with 0.1 ml of
CneF-184A emulsified in an equal part of CFA at each of two sites at
the base of the tail. Control mice were injected following the same
procedure with sterile physiological saline emulsified in CFA
(14). Six days after immunization, mouse footpads were injected with CneF-184A, other antigen preparations, or saline and
footpad swelling was measured 24 h later as previously described (14). Swelling is proportional to the level of DTH
reactivity to the test antigen (14). Typically, five animals
per group were used for assessment of levels of DTH reactivity and for
controls. Means, standard errors of the means, and unpaired Student's
t test results were used to analyze the footpad data.
Differences between groups with P values of 0.05 or less
were taken as significant.
Nucleotide sequence accession number. Sequence data from
pAM850 has been deposited with GenBank (accession number GI 266842).
 |
RESULTS |
Characterization of DTH activity in CneF from Cap-67 and its
fractions.
An extract of the culture supernatant from the
acapsular strain Cap67 (CneF-Cap67) was prepared in a similar manner to
CneF-184A, and the two were compared for their ability to stimulate an
anticryptococcal DTH response (Fig. 1).
In mice previously immunized with CneF-184A emulsified in CFA,
CneF-Cap67 elicited a significant level of DTH reactivity as measured
by the footpad-swelling response. The magnitude of the DTH reaction to
CneF-Cap67 was about half of that induced by CneF-184A. Also shown in
Fig. 1, deglycosylation of CneF-Cap67 with hydrogen fluoride
(HF-CneF-Cap67) did not reduce the DTH response.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
DTH reactions induced by a culture filtrate antigen
prepared from acapsular C. neoformans-isolated Cap-67. Mice
were immunized with CneF-184A-CFA or injected with sterile
physiological saline (SPSS)-CFA at two sites subcutaneously at the base
of the tail 6 days before being footpad tested with CneF-184A,
CneF-Cap67 (Cap 67), or HF-treated CneF-Cap67 (HF Cap 67). Five mice
were used per group. The experiment was repeated twice with similar
results. Vertical lines represent the standard error of the mean.
|
|
The HF-CneF-Cap67 was fractionated chromatographically by molecular
weight. Following the flowthrough (fraction 1), four peaks emerged, and
the fractions corresponding to each peak were pooled and concentrated.
These fractions were labeled fraction 2/3 (two overlapping peaks were
combined), fraction 4, and fraction 5 (Fig. 2). SDS-PAGE of fraction 4 suggested that
it was composed predominantly of bands also present in the two flanking
peaks, and therefore it was not analyzed further.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 2.
Gel filtration with Sephadex G-75 of HF-treated CneF
from the acapsular strain Cap-67. Bars indicate total protein for each
fraction. The regression line was calculated from molecular weight
markers (molecular weight is shown in thousands on the right-hand
axis).
|
|
Fractions 1, 2/3, and 5 were tested for their abilities to elicit a DTH
response in mice immunized with CneF-184A in CFA. As shown in Fig.
3, the flowthrough (fraction 1) did not
elicit an anticryptococcal DTH reaction, fraction 2/3 stimulated a
marginal level of DTH reactivity, and fraction 5 elicited footpad
swelling which was nearly half of that elicited by the reference
CneF-184A (Fig. 3). The level of DTH elicited by fraction 5 was
comparable to that elicited by unfractionated HF-CneF-Cap67 (Fig. 1).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
DTH reactions elicited in CneF-CFA-immunized mice with
fractions 1, 2/3, or 5 obtained from the fractionation of HF-CneF-Cap67
on a Sephadex G-75 column. Mice were immunized or injected with
saline-CFA as indicated in the legend to Fig. 1. Footpad testing was
done with CneF-184A as a control or with the designated antigen
fraction.
|
|
Molecular mass standards, which were run in the same column, indicated
that fraction 5 contained proteins ranging from 25 to less than 13 kDa.
An analogous fraction restricted to the molecular mass range between 10 and 30 kDa was prepared by differential centrifugation separation of
HF-CneF-Cap67 (see Materials and Methods). When this fraction, referred
to as fraction B, was injected into the hind footpads of immune mice at
1 µg of protein per pad, it elicited a marginal response, but when it
was injected at 3 µg of protein per pad, it elicited a response
equivalent to the response elicited by CneF-Cap67 or HF-CneF-Cap67
(Fig. 4).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
DTH reactions elicited in CneF-CFA-immunized mice with
fractions derived from HF-CneF-Cap67 by differential centrifugation
using Centricon 10 and Centricon 30 centrifugal filter devices. Mice
were immunized or injected with saline-CFA as indicated in the legend
to Fig. 1. Footpad testing was done with CneF-184A as a control or with
the 10-30 kDa component at two different protein concentrations.
|
|
Protein sequencing.
Fraction 5 from HF-CneF-Cap67 contained a
prominent protein doublet migrating at approximately 20 kDa in
SDS-PAGE. The two bands were excised from SDS-PAGE gels for detailed
analysis. The total amino acid compositions of the proteins in the two
bands were very similar (data not shown), and the first 20 amino acids of their N-terminal sequences (DTPYLGSVLTTAANGAASVS) were identical. The N-terminal amino acid was not methionine, suggesting that the
full-length gene product may be a signal peptide or other leader
sequence that was absent in the SDS-PAGE-purified protein.
The more abundant and slower-migrating protein of the pair was
subjected to proteolytic digestion, and the HPLC-purified fragments were submitted for amino acid sequencing. Digestion with trypsin yielded several small fragments, none of which resulted in sequences longer than 4 amino acids. However, digestion with Lys-C produced longer peptides. Four of the HPLC peaks from the Lys-C digestion (identified as peaks 56, 62, 64, and 65) ranged from 6 to 18 amino acids, and their sequences could be superimposed. Also, two other HPLC
peaks (identified as peaks 11 and 16) were very similar to each other
in their amino acid sequences. The biochemically determined sequences
from the N terminus, peak 62, peak 11, and an additional HPLC peak
(peak 15) are shown in Fig. 5 in relation
to the deduced sequence from the DHA1 gene, which was cloned
as described below.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 5.
Complete cDNA with flanking genomic sequences and amino
acid sequence of DHA1. The boxed sequence indicates a
putative signal peptide, and the inverted triangles indicate introns of
60, 55, 61, and 53 bp from 5' to 3', respectively. Downstream of the
stop codon is a polyadenylation signal (as indicated). The arrows
indicate the beginning and the end of the RT-PCR clone, and the
sequences upstream and downstream were obtained from genomic clones.
Underlined are the sequences of the two oligonucleotides used for the
RT-PCR. Underlined peptide sequences match those obtained from
sequencing the amino terminus and Lys-C peptides. X indicates an amino
acid for which biochemical analysis could not distinguish between S, T,
V, and G. The dash indicates that no amino acid was identified by
biochemical sequencing, and the bold N indicates a glycosylated
asparagine, both by biochemically determined molecular weight and by
the consensus sequence NASE.
|
|
Cloning and expression of the putative DTH-eliciting antigen.
From the N-terminal sequence and the two groups of similar internal
sequences (HPLC peaks 56, 62, 64, and 65 and HPLC peaks 11 and 16),
degenerate oligonucleotides were designed and used as primers for
RT-PCR amplification. Only the combination of oligonucleotides OAM51
(from the N-terminal sequence) and OAM46 (from peaks 56, 62, 64, and
65) produced a product of 776 bp. This was cloned to generate plasmid
pAM830. Sequencing of this clone confirmed that it contained the coding
sequences for both primers. In addition, the deduced amino acid
sequence of pAM830 contained a segment of amino acids which
corresponded to the peptides of HPLC peaks 11 and 62 (Fig. 5). A
C. neoformans strain B3501
phage genomic library was
screened with pAM830, and 12 positive clones were obtained. From one of
these clones, a HindIII fragment, of approximately 4 kb,
was subcloned to form plasmid pAM850. The fragment was completely sequenced and was found to contain the entire gene, which we have termed DHA1 for "delayed hypersensitivity antigen 1."
Subsequent studies were carried out to isolate the 5' end of the
DHA1 cDNA, which was missing from the RT-PCR product.
Attempts to obtain clones from an available C. neoformans
phage cDNA library prepared from strain B-3501 were unsuccessful.
Therefore, 5' RACE-PCR was performed using RNA isolated from Cap-67,
and this provided the missing 5' end of the transcript. With this information, a cDNA containing the complete DHA1 ORF was
synthesized by RT-PCR with oligonucleotides 5' of the ATG and 3' of the
stop codon of the putative ORF from genomic clone pAM850 (Fig. 5).
Comparison of the genomic and cDNA sequences showed the ORF to encode a
protein of 327 amino acids with a mass of about 34 kDa. It has
similarity to the product of a developmentally regulated gene,
priA, from Lentinus edodes (shiitake mushroom),
associated with fruiting-body formation (GenBank accession number
X60956) (9). Of special note, there is extensive similarity
between a "zinc cluster"-like motif located at the C terminus of
PRIA and a 79-amino-acid sequence near the C terminus of DHA1 (Fig. 6). Additional sequence analyses indicate
that there is a putative signal peptide sequence, four introns of 60, 55, 61, and 53 bp from 5' to 3', and a putative Kozak sequence. The
deduced amino acid sequence contains a single motif for N-glycosylation
(NASE) at amino acid 276 of the full-length protein. Furthermore, all peptide sequences obtained by either tryptic or Lys-C digestion can be
found within the cDNA sequence, four of which are represented in Fig.
5. The matches between the biochemically sequenced and the deduced
amino acid sequences demonstrate that the protein that had been
biochemically purified from CneF-Cap67 is encoded by the plasmid
pAM850.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 6.
Alignment of similar amino acid sequences from PRIA of
L. edodes and DHA1 of C. neoformans. White
lettering on a black background indicates identity; + indicates
conserved amino acid substitutions.
|
|
DTH response in mice elicited by the expression product of the
gene.
To test whether the protein encoded by DHA1 could
elicit DTH, the cloned cDNA from pAM850 was subcloned into the
bacterial expression vector pET32a to generate pAM890 and the
recombinant fusion protein was purified from bacterial cultures as
indicated in Materials and Methods. When the fusion protein was tested
for DTH stimulation (Fig. 7), it elicited
a DTH response analogous to that shown by CneF-Cap67 (Fig. 1) or
HF-CneF-Cap67 (Fig. 1 and 4).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 7.
DTH reactions elicited in CneF-CFA-immunized mice with
the DHA1 fusion protein (rDHA1). Mice were immunized or injected with
saline-CFA as indicated in the legend to Fig. 1. Footpad testing was
done with CneF-184A, with the expression of vector without the DHA1
insert (Vector) or with rDHA1.
|
|
 |
DISCUSSION |
Vaccination of mice with extracts of C. neoformans
results in a CMI response that can be detected by subsequent antigenic stimulation to elicit DTH responses, as measured by footpad swelling (13). In the studies reported here, we have identified one
gene whose product contributes to this process.
Our initial observations indicated that CneF from an acapsular mutant
(Cap-67) of C. neoformans was able to stimulate a DTH response in mice vaccinated with CneF from the encapsulated strain, 184A. Deglycosylation of CneF-Cap67 with anhydrous hydrogen fluoride did not affect its ability to elicit a positive DTH response in mice
immunized against C. neoformans. We included this
deglycosylation step because it had been very helpful in separating
protein antigens in extracts from another fungal pathogen,
Coccidioides immitis (5). Although most of the
carbohydrate is removed by anhydrous hydrogen fluoride, residual
monosaccharides would be expected to be present after this treatment
(19). By biochemical fractionation, the predominant DTH
activity was localized to a pair of protein bands approximately 20 kDa
in size. Since all biochemical analysis was carried out after
deglycosylation, we are not sure of the apparent molecular weight of
DHA1 prior to this step, and with glycosylation, it could be
considerably larger. The total amino acid composition and N-terminal
sequence determinations showed the two proteins to be virtually
identical, and we presume that one is a partial degradation product of
the other and that both are derived from the same gene. Using
biochemically determined N-terminal and internal amino acid sequences,
the gene corresponding to the protein, DHA1, has been
cloned. The deduced sequence, excluding the signal peptide, is 305 amino acids and has a mass approximately 10 kDa greater than that
estimated for the biochemically purified protein. Although we did not
determine the C-terminal amino acid sequences of the biochemically
purified protein, most if not all of the mature protein appears to be
intact in the 20-kDa protein since the internal fragment peak 15 is
located 18 amino acids from the C terminus (Fig. 5). Another amino acid
sequence (peak 11) also corresponds to a portion of the deduced
protein, further indicating that DHA1 encodes the protein
associated with DTH activity in fraction 5 of CneF-Cap67.
There is a striking similarity between the deduced C. neoformans DHA1 polypeptide and that of another basidiomycete
fungus, the PRIA protein of L. edodes (9). PRIA
is a developmentally regulated protein expressed most prominently
during early fruiting-body development in the shiitake mushroom. The
DHA1 polypeptide is cysteine rich, with 22 Cys residues in the
305-residue mature protein (7.2%). Fifteen of these residues are
positionally conserved between DHA1 and PRIA. The two polypeptides have
a high degree of similarity in their C termini, with 37% identical
residues and an additional 19% conservative changes over a
79-amino-acid region (Fig. 6). This region resembles the zinc cluster
domain of metallothionines responsible for binding zinc and other heavy metals (20). Evidence suggesting that the PRIA
polypeptide interacts with zinc comes from experiments in which it
caused sensitivity to zinc and other heavy metals when expressed in
Escherichia coli. Although the DHA1 protein is found in the
C. neoformans extracellular filtrate, its biological
function is unknown. The PRIA protein has not been localized yet. The
structural similarities between DHA1 and PRIA suggest possible avenues
for future work to define the role of DHA1 in C. neoformans.
Our findings indicate that the fusion protein resulting from expression
of DHA1 does not induce footpad reactions in
saline-CFA-injected control mice but does elicit DTH reactions in mice
immunized with CneF-184A. In previous studies, mice vaccinated with
CneF-184A in CFA not only responded to subsequent CneF-184A footpad
challenge with a positive DTH response but also were protected against
infection with C. neoformans (13). These
observations raise the possibility that vaccination with the
recombinant antigen of DHA1 may afford protection against a
cryptococcal infection. However, it is not yet known whether the
stimulus for DTH is the same which evokes protection. Clearly, this is
an important question to pursue in future studies.
Our findings do not preclude the possibility that one or more other
proteins may exist in encapsulated strains of C. neoformans which possess DTH-stimulating activity. Of note in our work, the magnitude of the DTH response elicited by either the purified or the
recombinant purified protein was consistently no more than half that
elicited by CneF-184A. In work by Murphy et al., the MP fraction of
CneF-184A was identified as predominantly associated with the murine
CMI response (15). SDS-PAGE analysis of CneF-184A indicates
that the MP fraction is considerably larger than that identified in
CneF-Cap67. Although our immunological experiments suggest that
DHA1 exists in strain 184A, this has not yet been demonstrated. At least one glycosylation site exists in the ORF of
DHA1. Glycosylation of the protein would increase its
molecular weight and result in lower mobility in SDS-PAGE. It is also
possible that other proteins or glycoproteins which are present in
CneF-184A and that are unrelated to the antigen from DHA1
contribute to the anticryptococcal DTH reactivity. Further work is
needed to clarify this issue as well.
 |
ACKNOWLEDGMENTS |
This work was supported in part by the U.S. Department of
Veterans Affairs, The Arizona Disease Control Research Commission, and
Public Health Service grant Al-15716 from the National Institute of
Allergy and Infectious Diseases.
We thank Erik Jacobsen for his gift of the acapsular mutant used in
this study and John H. Law for his helpful suggestions and
encouragement. Fabiana Ahumada provided very valuable technical assistance with expression of the recombinant antigen.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Valley Fever
Center for Excellence (1-111), 3601 South Sixth Ave., Tucson, AZ 85723. Phone: (520) 792-1450 ext. 6793. Fax: (520) 629-4738. E-mail: spherule{at}u.arizona.edu.
Editor:
V. J. DiRita
 |
REFERENCES |
| 1.
|
Buchanan, K. L., and J. W. Murphy.
1993.
Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.
Infect. Immun.
61:2854-2865[Abstract/Free Full Text].
|
| 2.
|
Casadevall, A., and J. R. Perfect.
1998.
Cryptococcus neoformans.
ASM Press, Washington, D.C.
|
| 3.
|
Cauley, L. K., and J. W. Murphy.
1979.
Responses of congenitally athymic (nude) and phonotypically normal mice to Cryptococcus neoformans infection.
Infect. Immun.
23:644-651[Abstract/Free Full Text].
|
| 4.
|
Dubois, M.,
K. A. Gilles,
J. K. Hamilton,
P. A. Rebers, and F. Smith.
1956.
Colorimetric method for the determination of sugars and related substances.
Anal. Chem.
28:350-356[CrossRef].
|
| 5.
|
Dugger, K. O.,
J. N. Galgiani,
N. M. Ampel,
S. H. Sun,
D. M. Magee,
J. Harrison, and J. H. Law.
1991.
An immunoreactive apoglycoprotein purified from Coccidioides immitis.
Infect. Immun.
59:2245-2251[Abstract/Free Full Text].
|
| 6.
|
Graybill, J. R.,
L. Mitchell, and D. J. Drutz.
1979.
Host defense in cryptococcosis. III. Protection of nude mice by thymus transplantation.
J. Infect. Dis.
140:546-552[Medline].
|
| 7.
|
Hoy, J. F.,
J. W. Murphy, and G. G. Miller.
1989.
T cell response to soluble cryptococcal antigens after recovery from cryptococcal infection.
J. Infect. Dis.
159:116-119[Medline].
|
| 8.
|
Jacobson, E. S., and D. J. Ayers.
1979.
Auxotrophic mutants of Cryptococcus neoformans.
J. Bacteriol.
139:318-319[Abstract/Free Full Text].
|
| 9.
|
Kajiwara, S.,
K. Yamaoka,
K. Hori,
H. Miyazawa,
T. Saito,
T. Kanno, and K. Shishido.
1992.
Isolation and sequence of a developmentally regulated putative novel gene, priA, from the basidiomycete Lentinus edodes.
Gene
114:173-178[CrossRef][Medline].
|
| 10.
|
Kwon-Chung, K. J., and J. E. Bennett.
1992.
Medical mycology.
Lea & Febiger, Philadelphia, Pa.
|
| 11.
|
Mitchell, T. G., and J. R. Perfect.
1995.
Cryptococcois in the era of AIDS 100 years after the discovery of Cryptococcus neoformans.
Clin. Microbiol. Rev.
8:515-548[Abstract].
|
| 12.
|
Murphy, J. W., and G. C. Cozad.
1972.
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.
Infect. Immun.
5:896-901[Abstract/Free Full Text].
|
| 13.
|
Murphy, J. W.,
J. A. Gregory, and H. W. Larsh.
1974.
Skin testing of guinea pigs and footpad testing of mice with a new antigen for detecting delayed hypersensitivity to Cryptococcus neoformans.
Infect. Immun.
9:404-409[Abstract/Free Full Text].
|
| 14.
|
Murphy, J. W., and J. W. Moorhead.
1982.
Regulation of cell-mediated immunity in Cryptococcus.
J. Immunol.
128:276-283[Abstract].
|
| 15.
|
Murphy, J. W.,
R. L. Mosley,
R. Cherniak,
G. H. Reyes,
T. R. Kozel, and E. Reiss.
1988.
Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens.
Infect. Immun.
56:424-431[Abstract/Free Full Text].
|
| 16.
|
Murphy, J. W., and N. Pahlavan.
1979.
Cryptococcal culture filtrate antigen for detection of delayed-type hypersensitivity in cryptococcosis.
Infect. Immun.
25:284-292[Abstract/Free Full Text].
|
| 17.
|
Murphy, J. W.,
F. Schafer,
A. Casadevall, and A. Adesina.
1998.
Antigen-induced protective and non-protective cell-mediated immune components against Cryptococcus neoformans.
Infect. Immun.
66:2639.
|
| 18.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 19.
|
Shively, J. E.
1986.
Reverse-phase HPLC isolation and microsequencing, p. 60-64.
In
J. E. Shively (ed.), Methods of protein microcharacterization. A practical handbook. Humana Press, Clifton, N.J.
|
| 20.
|
Vallee, B. L.,
J. E. Coleman, and D. S. Auld.
1991.
Zinc fingers, zinc clusters and zinc twists in DNA-binding protein domains.
Proc. Natl. Acad. Sci. USA
88:999-1003[Abstract/Free Full Text].
|
Infection and Immunity, November 2000, p. 6196-6201, Vol. 68, No. 11
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mansour, M. K., Yauch, L. E., Rottman, J. B., Levitz, S. M.
(2004). Protective Efficacy of Antigenic Fractions in Mouse Models of Cryptococcosis. Infect. Immun.
72: 1746-1754
[Abstract]
[Full Text]
-
Biondo, C., Beninati, C., Bombaci, M., Messina, L., Mancuso, G., Midiri, A., Galbo, R., Teti, G.
(2003). Induction of T Helper Type 1 Responses by a Polysaccharide Deacetylase from Cryptococcus neoformans. Infect. Immun.
71: 5412-5417
[Abstract]
[Full Text]
-
Huang, C., Nong, S.-h., Mansour, M. K., Specht, C. A., Levitz, S. M.
(2002). Purification and Characterization of a Second Immunoreactive Mannoprotein from Cryptococcus neoformans That Stimulates T-Cell Responses. Infect. Immun.
70: 5485-5493
[Abstract]
[Full Text]
-
Biondo, C., Beninati, C., Delfino, D., Oggioni, M., Mancuso, G., Midiri, A., Bombaci, M., Tomaselli, G., Teti, G.
(2002). Identification and Cloning of a Cryptococcal Deacetylase That Produces Protective Immune Responses. Infect. Immun.
70: 2383-2391
[Abstract]
[Full Text]
-
Mansour, M. K., Schlesinger, L. S., Levitz, S. M.
(2002). Optimal T Cell Responses to Cryptococcus neoformans Mannoprotein Are Dependent on Recognition of Conjugated Carbohydrates by Mannose Receptors. J. Immunol.
168: 2872-2879
[Abstract]
[Full Text]
-
Levitz, S. M., Nong, S.-h., Mansour, M. K., Huang, C., Specht, C. A.
(2001). Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc. Natl. Acad. Sci. USA
10.1073/pnas.181331398v1
[Abstract]
[Full Text]
-
Levitz, S. M., Nong, S.-h., Mansour, M. K., Huang, C., Specht, C. A.
(2001). Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc. Natl. Acad. Sci. USA
98: 10422-10427
[Abstract]
[Full Text]